Phase I Study of Combination Therapy with OBP-301, Atezolizumab and chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2063200044

Enrollment

Registered

2021-01-14

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Interventions

OBP-301:Specified dose is adminiistered into tumors endoscopically or transdermally. Atezolizumab:1200 mg IV infusion Q3W Cisplatin:Specified dose, IV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with the oral cavity, oropharynx, larynx, or hypopharynx histologically or cytologically confirmed who are unresectable or wishing organ preservation - When oropharynx cancer, HPV status is determined - Definitive chemoradiotherapy of CDDP and IMRT are indicated. - ECOG Performance Status (PS) is 0 to 1.

Exclusion criteria

Exclusion criteria: - The stage for primary tumor or cervical nodes is unknown. - Prior treatment with definitive local therapy or systemic therapy for the head and neck cancer. - Prior treatment with radiotherapy over the cranial base to clavicle.

Design outcomes

Primary

Measure	Time frame
safety observation	—

Secondary

Measure	Time frame
efficacy tumor assessment, observation	—

Contacts

Public ContactClinical trials information

Chugai Pharmaceutical Co., Ltd.

clinical-trials@chugai-pharm.co.jp+81-120-189-706

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026